ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2014; 4(4):412-419. doi:10.7150/thno.7324 This issue Cite
Short Research Communication
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
1. Department of Nuclear Medicine, University Hospital Freiburg, Germany.
2. Department of Radiation Oncology, University Hospital Freiburg, Germany.
3. Department of Urology, University Hospital Freiburg, Germany.
4. Department of Radiology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
5. German Cancer Consortium (DKTK).
6. Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Switzerland.
7. Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
* First authors (both authors contributed equally to this work): Gesche Wieser (resident, MD) and Rosalba Mansi (PhD), Hugstetter Straße 55, 79102 Freiburg i. Br., Germany, Phone: +49-761-27039160, Fax: +49-761-27039300, gesche.wieser@uniklinik-freiburg.de or rosalba.mansi@uniklinik-freiburg.de
Citation:
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics 2014; 4(4):412-419. doi:10.7150/thno.7324. https://www.thno.org/v04p0412.htm
Other stylesAbstract
Ex vivo studies have shown that the gastrin releasing peptide receptor (GRPr) is overexpressed on almost all primary prostate cancers, making it a promising target for prostate cancer imaging and targeted radiotherapy.
Methods: Biodistribution, dosimetry and tumor uptake of the GRPr antagonist 64Cu-CB-TE2A-AR06 [(64Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-LeuNH2] were studied by PET/CT in four patients with newly diagnosed prostate cancer (T1c-T2b, Gleason 6-7).
Results: No adverse events were observed after injection of 64Cu-CB-TE2A-AR06. Three of four tumors were visualized with high contrast [tumor-to-prostate ratio > 4 at 4 hours (h) post injection (p.i.)], one small tumor (T1c, < 5% tumor on biopsy specimens) showed moderate contrast (tumor-to-prostate ratio at 4 h: 1.9). Radioactivity was cleared by the kidneys and only the pancreas demonstrated significant accumulation of radioactivity, which rapidly decreased over time.
Conclusion: 64Cu-CB-TE2A-AR06 shows very favorable characteristics for imaging prostate cancer. Future studies evaluating 64Cu-CB-TE2A-AR06 PET/CT for prostate cancer detection, staging, active surveillance, and radiation treatment planning are necessary.
Keywords: Gastrin releasing peptide receptor, bombesin, PET/CT, prostate cancer.
Citation styles
APA
Wieser, G., Mansi, R., Grosu, A.L., Schultze-Seemann, W., Dumont-Walter, R.A., Meyer, P.T., Maecke, H.R., Reubi, J.C., Weber, W.A. (2014). Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 4(4), 412-419. https://doi.org/10.7150/thno.7324.
ACS
Wieser, G.; Mansi, R.; Grosu, A.L.; Schultze-Seemann, W.; Dumont-Walter, R.A.; Meyer, P.T.; Maecke, H.R.; Reubi, J.C.; Weber, W.A. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics 2014, 4 (4), 412-419. DOI: 10.7150/thno.7324.
NLM
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics 2014; 4(4):412-419. doi:10.7150/thno.7324. https://www.thno.org/v04p0412.htm
CSE
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. 2014. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics. 4(4):412-419.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.